TRex Bio (TRXB.US) IPO priced at $14-16 per share, plans to raise $125 million; Eli Lilly intends to subscribe for $13 million
TRex Bio announced the terms of its initial public offering (IPO) on Monday.
According to Golden Ten Data, biotechnology company TRex Bio (TRXB.US), which focuses on developing drugs for autoimmune and inflammatory diseases, announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 8.3 million shares at a price of $14 to $16 per share, raising $125 million. Eli Lilly (LLY.US) intends to subscribe to $13 million worth of shares in this offering (accounting for 10% of the total transaction). Based on the midpoint of the offering price range, TRex Bio's fully diluted market capitalization will reach $453 million.
TRex Bio is a clinical-stage biopharmaceutical company dedicated to developing drugs that enhance the function of regulatory T cells (Treg) in inflamed human tissues, aiming to restore immune balance and repair barrier damage rather than broadly suppressing the immune system. Its Deep Biology platform enables the mapping of Treg functional profiles in human skin, gut, and lung tissues, thereby identifying targets and validating them through proprietary in vitro Treg models and high-throughput functional assay methods.
Its main drug candidate, TRB-061, is a TNFR2 agonist currently in a Phase 1b clinical trial for the treatment of moderate-to-severe atopic dermatitis, with preliminary data expected to be released in mid-2027. Another wholly owned candidate, TRB-071, targets CD30 for the treatment of inflammatory bowel disease and is expected to enter Phase 1 clinical trials in the first half of 2027. Eli Lilly is both an investor and a discovery partner and is currently advancing a third candidate discovered on the platform into a Phase 2a clinical trial for lupus treatment.
This South San Francisco, California-based company was founded in 2018 and plans to list on the Nasdaq under the ticker "TRXB". JPMorgan, Evercore ISI, Cantor Fitzgerald, Stifel, and Wedbush Securities are joint bookrunners for the offering.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Evogene announces special shareholder meeting
Evogene will hold a special general meeting of shareholders in Rehovot, Israel on Nov. 10, 2026. Shareholders will vote on electing Oz Adler and Dr. Adi Zuloff-Shani to the board. Ballots will also cover the election of Itay Maroz and Shahar Zadok, subject to approval of a cooperation agreement. The meeting will also vote on a cooperation agreement between Evogene and L.I.A. Pure Capital and Invest-Pro Shukai Hon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004722), on October 06, 2026, and is solely responsible for the information contained therein.
UK names 6 banks to lead first digitally native government bond
Altaris Completes Acquisition of Simulations Plus
02:57 PM EDT, 10/06/2026 (MT Newswires) -- Simulations Plus (SLP) said Tuesday that affiliates of Altaris have completed the acquisition of the company. The transaction price was $375 million, with each Simulations shareholder receiving $18.50 in cash per share, according to an earlier statement. As a result of the acquisition, Simulations said it has become a privately held company and its common stock will no longer trade on the Nasdaq Global Select Market.
Ondo Finance brings pre-IPO AI exposure on-chain — But there’s a catch
Crypto prices
More
